Morningstar's Applied Genetic Technologies Corp Stock Analysis
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile - AGTC
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
Alachua, FL, 32615